Predictors of the location of multiple sclerosis relapse

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 10, 2008, Pages 1190-1193

  Deen, S ^a   Bacchetti, P ^b   High, A ^b   Waubant, E ^a  

^a UCSF Multiple Sclerosis Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; STEROID;

ADULT; ARTICLE; BRAIN; BRAIN STEM; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; GENDER; HEREDITY; HUMAN; IMMUNOLOGY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; OPTIC NERVE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE; RELAPSE; RISK; SPINAL CORD; SYMPTOM;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN STEM; CEREBELLUM; CEREBRUM; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; OPTIC NERVE; PEPTIDES; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; SPINAL CORD;

EID: 53149137812     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2007.136440     Document Type: Article

References (18)

1. Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-8.
2. West T, Wyatt M, High A, et al. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67:809-13.
3. Butterfield RJ, Blankenhorn EP, Roper RJ, et al. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000;157:637-45.
4. Krishnamoorthy G, Lassmann H, Wekerle H, et al. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006;116:2385-92.
5. Bettelli E, Pagany M, Weiner HL, et al. Myelin oligodendrocye glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003;197:1073-81.
6. Berger T, Weerth S, Kojima K, et al. Experimental autoimmune encephalomyelitis: the antigen specificity of T-lymphocyets determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997;76:355-64.
7. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
10. Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-55.
11. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7.
12. West T, Wyatt M, High A, et al. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67:809-13.
13. Waubant E, Goodkin DE, Sloan R, et al. A pilot study of MRI activity before and during interferon beta-1a therapy. Neurology 1999;53:874-6.
14. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150- 8.
15. Daniel PM, Lam DK, Pratt OE. Comparison of the vascular permeability of the brain and the spinal cord to mannitol and inulin in rats. J Neurochem 1985;5:647-9.
16. Pan W, Banks W, Kastin A. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol 1997;76:105-11.
17. Juhler M, Barry Dl, Offner H, et al. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat. Brain Res 1984;302:347-55.
18. Lassmann H, Brunner C, Bradl M, et al. Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol (Berl) 1988;75:566-76.